MAG and Stroke: Cramer et al. conducted a double-blinded placebo-controlled pilot study of GSK249320, a monoclonal anti-MAG (myelin-associated glycoprotein) antibody, in patients presenting a moderate walking disability after stroke (0.5 m/sec on average 5 days after stroke).